Physician profile
Payal Daya
NPI 1033649348
$723.12
in general payments reported to CMS, 2019-2025
14 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.54 · 2022: $165 · 2023: $73.65 · 2024: $78.97 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.91 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $151.63 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $107.30 | 2025 | |
| Exact Sciences Corporation | $74.40 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $54.43 | 2022-2024 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $41.06 | 2025 | |
| Sanofi Pasteur INC. | $20.63 | 2025 | |
| Dynavax Technologies Corporation | $19.14 | 2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $18.96 | 2024 | Spravato |
| Pfizer INC. | $18.15 | 2025 | |
| Merck Sharp & Dohme LLC | $15.95 | 2025 | Gardasil 9 |
| Dexcom, INC. | $15.76 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $15.45 | 2025 | |
| Amgen INC. | $14.35 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Daya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.